November 11, 2026

Wichtigste Nachrichten

Philipp Amthor und Augustus Intelligence: Aktienoptionen, Lobbybrief, Luxusreisen – wie ein Lobbyskandal die Regeln des Bundestags veränderte

Philipp Amthor vermittelte einem kaum bekannten US-Start-up Zugang ins Wirtschaftsministerium, saß später im Board und erhielt 2.817 Aktienoptionen. Die Staatsanwaltschaft sah keinen Anfangsverdacht, die damaligen Transparenzregeln griffen nicht – und.

Mehr lesen

Dell Stock Before Q2 Earnings: The $51 Billion AI Server Backlog Is Huge — but Can Margins Keep Up?

Dell reports Q2 FY2027 results tonight with an AI server backlog above $50 billion and the stock near record highs. This deep dive asks whether AI infrastructure growth can translate.

Mehr lesen

Palo Alto Networks Stock Before Q4 Earnings: CyberArk, AI Security and the $21 Billion Backlog Test

Palo Alto Networks reports FY2026 results tonight. The stock has rallied into the print, CyberArk has transformed the revenue base, and guidance implies another 32% quarter. This deep dive explains.

Mehr lesen

NIO Stock 2026: 18.5% Vehicle Margin, Profitability & Valuation

NIO’s Q2 2026 revenue rose 69%, vehicle margin reached 18.5%, and adjusted operating profit turned positive — but the stock still trades near its 52-week low. This analysis asks whether.

Mehr lesen

BYD Stock 2026: Exports +68%, 53% of Revenue Now Overseas — Is 24x Earnings Still Cheap?

BYD stock 2026: exports rose about 68%, overseas revenue reached 53% of sales and valuation sits near 24x earnings. See market cap, margins and risks.

Mehr lesen

Congressional Stock Trading 2026: STOCK Act, Senate Ban & Evidence

U.S. senators can still own and trade individual stocks, but trading on material nonpublic information is illegal. This deep dive separates suspicion from proof, explains the STOCK Act and Senate.

Mehr lesen

Apple M6 & John Ternus: 2nm AI Silicon, Buybacks & Valuation

Apple enters a new CEO era just days after launching its first 2nm M6 chip. I examine why custom silicon, on-device AI and a $4.7 trillion valuation make the next.

Mehr lesen

Moderna Stock 2026: Phase 3 Cancer Vaccine Wins — Is the MRNA Rally Already Too Far?

Moderna’s Phase 3 melanoma trial with Merck met its primary and key secondary endpoints. MRNA now has real oncology proof, but Q2 revenue was only $0.1B and cash burn remains.

Mehr lesen

Nebius Stock 2026: AI Cloud Growth, $5.75B Debt & Valuation

Nebius stock has become one of the market’s hottest AI infrastructure trades. Revenue is exploding and capacity is sold out, but $5.75 billion of new convertible debt changes the risk..

Mehr lesen

IREN Stock After the 13% Earnings Crash: Is This Still a Bitcoin Miner — or the Next AI Cloud Giant?

IREN stock fell about 13% after FY2026 earnings even as AI Cloud revenue doubled sequentially and contracted ARR reached $4 billion. The real question is whether the company’s financing-heavy pivot.

Mehr lesen